Erythropoietin enhances response to treatment in patients with advanced breast cancer [2]

Acta Oncologica

Volumn 43, Issue 6, 2004, Pages 594-597

  Larsson, Anna Maria ^a   Landberg, Göran ^a   Påhlman, Sven ^a,c   Albertsson, Maria ^b  

^a LUND UNIVERSITY   (Sweden)

^b University Hospital SÖS   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE;

ANEMIA; BONE LESION; BREAST CANCER; CHEMOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; FOLLOW UP; HEMOGLOBIN DETERMINATION; HORMONAL THERAPY; HUMAN; LETTER; LUNG INJURY; MAJOR CLINICAL STUDY; METASTASIS; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; SUPPLEMENTATION;

EID: 4844224301     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860410018179     Document Type: Letter

References (18)

1. Ludwig H, Fritz E. Overview of clinical trials on rHuEPO in cancer patients. In: Bokemeyer C, Ludwig H, eds. Anaemia in cancer, ESO Scientific Updates, VoL 6. 1st ed. Amsterdam: Elsevier Science B.V. 2001. p. 115-43.
2. Olsson A-M, Svensson J-H, Sundström J, et al. Erythropoietin treatment in metastatic breast cancer: effects on Hb, quality of life and need for transfusion. Acta Oncol 2002; 41: 517-24.
3. Littlewood TJ, Bajetta E, Nortier JWR, Vercammen E, Rapoport B. Effects of EPOetin Alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-74.
4. Glaser CM, Millesi W, Kornek GV, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50: 705-15.
5. Silver DF, Piver MS. Effects of recombinant human erythropoietin on the antitumour effect of Cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 1999; 73: 280-4.
6. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4: 459-60.
7. Henke M, Laszig R, Rübe C, Schäfer U, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled study. Lancet 2003; 362: 1255-60.
8. Acs G, Acs P, Beckwith SM, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001; 61: 3561-5.
9. Yasuda Y, Fujita Y, Matsuo T, et al. Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 2003; 24: 1021-9.
10. Westenfelder C, Baranowski RL. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000; 58: 647-57.
11. Caro JJ, Salas M, Ward A, Goss G. Anaemia as an independent prognostic factor for survival in patients with cancer. Cancer 2001; 91: 2214-21.
12. Vaupel P, Mayer A, Briest S, Höckel M. Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res 2003; 63: 7634-7.
13. Hockel M, Vaupel P. Tumour hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266-76.
14. Harris AL. Hypoxia: a key regulatory factor in tumour growth. Nature Rev Cancer 2002; 2: 38-47.
15. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994; 13: 139-68.
16. Helczynska K, Kronblad Å, Jögi A, et al. Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res 2003; 63: 1441-4.
17. Kronblad Å, Helczynska K, Nielsen NH, Emdin S, Påhlman S, Landberg G. Regional cyclin D1 overexpression or hypoxia correlate inversely with heterogeneous oestrogen receptor-alpha expression in human breast cancer. In vivo 2003; 17: 311-8.
18. Jögi A, Øra I, Nilsson H, et al. Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci 2002; 99: 7021-6.